Release Date: 17-Nov-2021
From more than 30 years, scientists have been developing therapeutic monoclonal antibodies which bind to single target antigens on cancer cell. Since their entry into the market, monoclonal antibodies are considered as major breakthrough in the management of cancer and have occupied top most position in the global cancer therapeutic market. Owing to their novel and targeted mechanism of action, monoclonal antibodies have been indicated for the management of wide range of cancers including lung, colorectal, breast, skin, and other cancers.
Keeping in mind, the high adoption rates of monoclonal antibodies and multifactorial nature of cancer, significant research has been carried out for enhancing the specificity of antibodies to target two or more antigens simultaneously. The designer antibodies/multispecific antibodies so developed have the ability to simultaneously target two or more pathways which are critical for the progression of cancer and have enhanced efficiency. Since the introduction of this idea, bispecific antibody or dual-binding antibody as well as trispecific antibodies have been developed for the management of cancer. To date, two bispecific antibodies have been approved for cancer including Blincyto and Rybervant. These drugs have shown high adoption rates due to their dual binding efficacy and ability to overcome the limitations of already approved therapies.
More recently, trispecific antibodies have also entered the clinical development. These are designed in a way in which one of three specificities is intended to redirect T or NK cells, and the other two targeting tumor associated antigens or tumor neoantigens, which are critical for the progression of cancer. Continuous research in this sector has led to the development of several formats including trispecific killer cell engagers (TriKE), trispecific NK cell engagers, trispecific T-cell activation constructs, and several others which have shown promising preclinical and clinical data. GTB-3550 is one of the leading trispecific antibody construct developed by GT Biopharma. Apart from this, several other constructs are also present in clinical trials and are expected to enter the market during the forecast period.
Global Trispecific Antibody Market Opportunity and Clinical Trials Insight 2028
Download Report:
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028
Download Report:
The designer antibodies have gained considerable momentum in the market due to several advantages offered by them in comparison to monoclonal antibodies. Designer antibody consists of single construct which has the ability to simultaneously bind two or more different antigens at the same time, thus enhancing the efficacy and specificity of treatment. In addition, these have the molecular size one-third to those of monoclonal antibody which ensures high penetrability and ability to cross blood brain barrier. Due to its enhanced functionality, it is believed that designer antibodies will result in few side effects and doses. In addition, development of single molecule instead of three has decreased the overall cost of production as well as number of clinical trials. The pipeline of designer antibodies is highly crowded and consists of several bispecific and trispecific antibody constructs which are expected to enter the market during the forecast period.
The increase in prevalence of cancer in coming years associated with high medical needs for the development of novel targeted drugs will drive the growth of designer cancer antibodies. Supportive government initiatives, increasing healthcare expenditure and awareness about novel targeted drugs will further propel the growth of market. Apart from this, the expiration of patents and subsequent development of biosimilars will also increase the competition among pharmaceutical giants. The major players working in market are Amgen, GT Biopharma, Sanofi, ImmunGene, Merck, Numab Therapeutics, and others. These companies have enetered into strategic alliances to utilize novel technology platforms for development of designer antibodies. For instance, in 2021, Eli Lilly and Merus collaborated on developing multispecific antibodies which will leverage Merus' proprietary Biclonicsandreg; platform along with the scientific and rational drug design expertise of Loxo Oncology at Lilly to research and develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies. The continuous research and investment will also drive the growth of designer antibodies market during forecast period.